Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database

Firkins, Stephen A.; Chittajallu, Vibhu; Flora, Bailey; Yoo, Heesoo; Simons-Linares, Roberto

doi:10.1007/s11695-024-07181-w

Cited by 4 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…1,2 Older generations of anti-obesity medications (AOMs) such as Phentermine, Orlistat, and Topiramate remain the most commonly prescribed weight loss medications, but are rapidly being replaced. 3 Bariatric surgery is the most effective treatment for severe obesity with over 50% of excess weight loss in most patients. 4 Despite this, many patients do not achieve obesity resolution.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Adverse Event Comparison between Glucagon-like Peptide-1 Receptor Agonists and Other Anti-Obesity Medications Following Bariatric Surgery

Samuels,

Niswender,

Roumie

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: The safety of Glucagon like Peptide 1 Receptor Agonists (GLP1RAs) following bariatric surgery remains largely unknown. This study aims to compare the incidence of adverse events (AEs) with GLP1RAs and other anti obesity medications (AOMs) after bariatric surgery. Methods: This single center retrospective cohort included patients (ages 16, 65) if they met the following criteria: underwent laparoscopic Roux en Y gastric bypass or sleeve gastrectomy (cohort entry date) and initiated AOMs. Subjects were categorized as users of FDA approved or off label AOMs or GLP1RAs AOMs if documented as receiving the medication on the cohort entry date or after. Non GLP1RA AOMs were Phentermine, Orlistat, Topiramate, Canagliflozin, Dapagliflozin, Empagliflozin, Naltrexone, Bupropion/Naltrexone, and Phentermine/Topiramate. GLP1RAs AOMs included: Semaglutide, Dulaglutide, Exenatide, Liraglutide. Primary outcome was AEs incidence. Logistic regression was used to determine the association of AOM exposure with AEs. Results: We identified 599 patients meeting inclusion criteria (83% female, median 47.8 years old (IQR 40.9, 55.4). Median surgery to AOM duration was 30 months (IQR 0, 62). GLP1RAs were not associated with higher odds of AEs (adjusted Odds Ratio, (aOR) 1.1, [95% CI 0.5, 2.6] and 1.1 [95% CI 0.6, 2.3] for GLP1RA versus FDA approved and Off Label AOMs, respectively. AOM initiation ≥12 months after surgery was associated with lower risk of AEs compared to <12 months (aOR 0.01. [95% CI 0.0, 0.01], p<0.001). Conclusion: GLP1RAs were not associated with an increased risk of AEs compared to nonGLP1RA AOMs in patients who previously underwent bariatric surgery. Prospective studies are needed to identify the optimal timeframe for initiation of GLP1RA.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Adverse Event Comparison between Glucagon-like Peptide-1 Receptor Agonists and Other Anti-Obesity Medications Following Bariatric Surgery

Samuels,

Niswender,

Roumie

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations

Conte

2024

OBES SURG

View full text Add to dashboard Cite

Obesity treatment in adolescents and adults in the era of personalized medicine

Sundbom,

Järvholm,

Sjögren

et al. 2024

J Intern Med

View full text Add to dashboard Cite

In this multi‐professional review, we will provide the in‐depth knowledge required to work in the expanding field of obesity treatment. The prevalence of obesity has doubled in adults and quadrupled in children over the last three decades. The most common treatment offered has been lifestyle treatment, which has a modest or little long‐term effect. Recently, several new treatment options—leading to improved weight loss—have become available. However, long‐term care is not only about weight loss but also aims to improve health and wellbeing overall. In the era of personalized medicine, we have an obligation to tailor the treatment in close dialogue with our patients. The main focus of this review is new pharmacological treatments and modern metabolic surgery, with practical guidance on what to consider when selecting and guiding the patients and what to include in the follow‐up care. Furthermore, we discuss common clinical challenges, such as patients with concurrent eating disorder or mental health problems, and treatment in the older adults. We also provide recommendations on how to deal with obesity in a non‐stigmatizing way to diminish weight stigma during treatment. Finally, we present six microcases—obesity treatment for persons with neuropsychiatric disorders and/or intellectual disability; obesity treatment in the nonresponsive patient who has “tried everything”; and hypoglycemia, abdominal pain, and weight regain after metabolic surgery—to highlight common problems in weight‐loss treatment and provide personalized treatment suggestions.

show abstract

Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database

Cited by 4 publications

References 34 publications

Adverse Event Comparison between Glucagon-like Peptide-1 Receptor Agonists and Other Anti-Obesity Medications Following Bariatric Surgery

Adverse Event Comparison between Glucagon-like Peptide-1 Receptor Agonists and Other Anti-Obesity Medications Following Bariatric Surgery

Comment on the Meta-analysis of Liraglutide for Weight Regain: Methodological Considerations

Obesity treatment in adolescents and adults in the era of personalized medicine

Contact Info

Product

Resources

About